Seeking Alpha

Seeking Alpha Portfolio App for iPad

5,142 people get NVS articles and Market Currents by email alert.

Get email alerts on NVS »

NVS

Novartis AG

5/20/2013, 1:06 PM ET

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Friday, December 31, 2010, 7:51 AM The FDA approved around 21 drugs in 2010, a relatively modest figure, with some of the most highly anticipated products delayed into next year or beyond. Among this year's FDA-approval winners: Amgen (AMGN), Roche (RHHBY.PK), Novartis (NVS), Acorda (ACOR) and Dendreon (DNDN). Comment!
Tuesday, December 21, 2010, 3:23 PM Xoma (XOMA +71%) shares skyrocket after a research report says the company’s once-a-month diabetes drug could lead a potential blockbuster class of drugs. Xoma's IL-1 inhibitor could give it an edge among competitors including Novartis (NVS), Amgen (AMGN) and Eli Lilly (LLY), according to Sumner Street Research. 2 Comments
Tuesday, December 21, 2010, 8:51 AM Multiple sclerosis patients and Novartis (NVS) are both setting their sights on Gilenya, a pill Novartis is working on to treat the degenerative disease. Analysts predict on average that Gilenya could generate $1.8B of annual revenue by 2014, and surge to $5.4B/year by 2016. Comment!
Wednesday, December 15, 2010, 9:00 AM Premarket gainers: ARAY +13%. CYPB +13%. SHZ +8%. NVS +8%. RF +7%. JOYG +5%. DYN +5%. MCP +4%. REE +4%.
Losers: MAXY -27%. AIB -5%. IVR -4%. Comment!
Wednesday, December 15, 2010, 3:08 AM Novartis (NVS) will merge with Alcon (ACL) in a deal worth $12.9B, paying Alcon $168 per share for the 23% stake Novartis doesn't already own. Novartis will reactivate a share buyback to minimize shareholder dilution. (PR) Comment!
Tuesday, December 7, 2010, 8:53 AM Credit Suisse upgrades Novartis (NVS) to Outperform from Neutral, saying the firm "now has the leading revenue growth for 2011 and 2012 relative to EU major pharma peers." Shares +1.9%. Comment!
Tuesday, November 30, 2010, 1:37 PM Novartis (NVS -1.7%) plans deep cuts in its American sales force - 1,400 jobs to be cut on Jan. 1, for a one-time cost of $85M - ahead of key patent expirations. The company, which employs 13,000 in its U.S. pharma business, is moving away from mass-market medicines toward specialty drugs. Comment!
Sunday, November 14, 2010, 3:21 PM Novartis (NVS) has its share of troubles, but Barron's says fears about the company's outlook may be overblown and shares are cheap, worth roughly what they were at the end of 2005 despite doubling its dividend and growing profits at double-digit rates. Even with looming patent expiries, Novartis boasts a diverse drug pipeline and shares could return 25-30% in the next two years. 1 Comment
Thursday, November 11, 2010, 8:23 AM Novartis (NVS -0.1%) will stop testing on its experimental lung-cancer drug after studies showed it had little or no impact on survival rates, and will take a $120M charge against Q4 earnings as a result. Novartis is eager to find replacement revenue for expiring patents, but is having only mixed success. 1 Comment
Monday, October 25, 2010, 12:11 PM Savient Pharmaceuticals (SVNT) resumes trading down 45% as it says a five-month auction process is reportedly going to end with no sale. Novartis (NVS) and Bristol-Myers Squibb (BMY) both passed on the acquisition as too expensive. Comment!
Monday, October 25, 2010, 8:21 AM Novartis (NVS +0.9%) says its Phase III trial of Menveo, a potential vaccine for infants against meningococcal disease, met its primary endpoints. The company will submit the vaccine for approval in the U.S. and elsewhere to treat children aged two months and older. Comment!
Monday, October 11, 2010, 8:01 AM Good news coming from ImmunoGen (IMGN), which announces updated FY'11 guidance, encouraging clinical data, and a collaborative agreement with Novartis (NVS). Premarket: IMGN +5.6%, NVS +0.5%. Comment!
Thursday, September 30, 2010, 1:12 PM Novartis (NVS -0.8%) settles with the U.S. Attorney for $422.5M, to resolve civil and criminal allegations on off-label promotion of its anticonvulsant Trileptal, and civil claims on five other drugs. 5 Comments
Friday, September 24, 2010, 7:52 AM Warner Chilcott (WCRX) will pay Novartis (NVS) $400M for the U.S. rights to bladder drug Enablex. The deal supercedes an existing co-promotion agreement. (PR) Comment!
Wednesday, September 22, 2010, 9:23 AM The FDA approves Novartis' (NVS) multiple sclerosis drug fingolimod for sale in the U.S. - the country's first oral drug for a disease typically treated with more cumbersome injections and infusions. Analysts say the new oral MS drugs could have significant commercial potential, possibly generating annual sales of $1B+. NVS +0.4% premarket. Comment!
Thursday, August 26, 2010, 9:07 AM Momenta Pharmaceuticals (MNTA) says a U.S. judge declined to stop the company and partner Novartis (NVS) from marketing a generic version of Sanofi-Aventis' (SNY) Lovenox blood thinner. MNTA +6.5%, NVS +0.7%, SNY -0.2% premarket. (PR) Comment!